Information updates

Updated ASCIA anaphylaxis resources

Over the past year ASCIA has updated and developed more than 24 online resources and 10 e-training courses to assist in the emergency treatment and management of anaphylaxis (severe allergic reactions).

Each year ASCIA online anaphylaxis resources are viewed more than 500,000 times and there are more than 100,000 registrations for the ASCIA anaphylaxis e-training courses.

The latest resources to be updated are ASCIA anaphylaxis checklists and e-training courses for prescribers (doctors and nurse practitioners), pharmacists and patients/carers, which now include information about two brands of adrenaline injectors, EpiPen® and Anapen®:

  • EpiPen® (300 mcg) and EpiPen® Jr (150 mcg) are available in Australia on the PBS, and in New Zealand.
  • Anapen® 500, Anapen® 300 and Anapen® 150 are available in Australia on the PBS.

Adrenaline injectors are prescribed as follows:

  • 150 mcg devices for children weighing 7.5 to 20kg.
  • 300 mcg devices for children weighing over 20kg and adults, including pregnant women.
  • 500 mcg or 300 mcg devices for children weighing over 50kg and adults, including pregnant women.

ASCIA has developed checklists to assist health professionals and patients/carers in the following ways:

Updated ASCIA anaphylaxis resources and e-training courses are available at www.allergy.org.au/anaphylaxis

ASCIA anaphylaxis education and training resources have been developed to assist with:

  • Prevention of anaphylaxis, including strategies to avoid exposure to allergens.
  • Emergency treatment of anaphylaxis, to prevent unnecessary death or disability.
  • Providing accessible, consistent and evidence-based information from a reliable source.

*ReadSpeaker is available on the ASCIA webpages for patients, consumers and carers, to improve access for people with:

  • Vision impairment, limited reading ability or learning disabilities, by allowing text to speech (TTS).
  • Non-English speaking backgrounds - information can be translated into 20 different languages by highlighting the text and selecting 'translate’.

ASCIA will continue to review and update anaphylaxis resources and e-training courses as new information is available. 

Mod ASCIA Member
Donate to AIFA
go to NAC website
About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia